To include your compound in the COVID-19 Resource Center, submit it here.

Zevalin ibritumomab tiuxetan regulatory update

IDPH said European approval for Zevalin radioimmunotherapy has been delayed because of compliance issues at the fill/finish provider,

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE